No­var­tis slots PhI car­dio­vas­cu­lar can­di­date in­to pipeline, pay­ing Ko­re­an part­ner $80M up­front

No­var­tis is pluck­ing a Phase I small mol­e­cule can­di­date out of Ko­rea that it be­lieves can treat a va­ri­ety of dis­eases — in­clud­ing cer­tain car­dio­vas­cu­lar con­di­tions …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.